Piet Sonnemann

Dr. Piet Sonnemann

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in Infection
Verified
Journal Article
Open access
PDF file
SHSebastian Herrmann
Sebastian Herrmann
SGStephanie Graefe
Stephanie Graefe
MCMaximilian Christopeit
Maximilian Christopeit
PSPiet Sonnemann
Piet Sonnemann
THTessa Hattenhauer
Tessa Hattenhauer
SMSibylle Mellinghoff
Sibylle Mellinghoff
Purpose: This study aims to evaluate the burden of respiratory syncytial virus (RSV) infections in patients with haematological diseases. It seeks to analyse the relevance of prevention, diagnosis and treatment of RSV infections. Methods: A multi-centre, retrospective study was conducted across University Hospitals in Cologne, Düsseldorf, Bonn, and the University Medical Centre Hamburg-Eppendorf between Jan 2016 and Aug 2023. All haematological patients with diagnosed RSV infection were included. The study focused on the incidence of RSV, underlying conditions, comorbidities, coinfections and clinical outcomes such as hospitalization, intensive care unit (ICU) admission and mortality. Results: Of 166 patients, 89 (53.6%) had signs of pneumonia and 37 (22.3%) were admitted to ICU due to RSV infection, while 20 (54%) of those were mechanically ventilated with median duration of 11 days (1,33; IQR:18). Mean age was 60 years (range 14–88). Sixteen patients (9.6%) were treated as outpatients, while 52 (31.3%) were hospitalized due to RSV infection; the median hospital stay was 16 days (IQR 25.25, range 0–97). 79 (47.6%) of patients presented with leukopenia and 57 (34.3%) with neutropenia. In total, 22 patients (13.3%) died within 30 days and 29 (17.5%) died within 90 days. Highest mortality rates were seen in patients with aggressive lymphoma (23.5%) and acute leukaemia (18%). Conclusion: RSV significantly impacts patients with haematological diseases, leading to high rates of hospitalization, ICU admission, and mortality. Preventive measures, such as vaccination, alongside early diagnosis and individualized management, are essential to reduce RSV-associated morbidity and mortality in this high-risk population.

19 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MSMartin Schönrock
Martin Schönrock
PSPiet Sonnemann
Piet Sonnemann
NMNina Michalowski
Nina Michalowski
MHMichael Heuser
Michael Heuser
FTFelicitas Thol
Felicitas Thol
SCSophia Cichutek
Sophia Cichutek
Background: Despite the development of targeted therapies in first-line AML, complete remissions (CR) cannot be achieved in 30–40%, and relapse rates remain high. In R/R AML the intensive treatment regimen of fludarabine, cytarabine, idarubicin combined with venetoclax (FLA-VIDA) showed improved remission rates compared to FLA-IDA. In this retrospective single-center analysis, we investigated the efficacy and safety of dose-reduced FLA-IDA with and without venetoclax to minimize the risk of infectious complications and excessive myelosuppression; Methods: Between 2011 and 2023, 89 R/R AML patients were treated with dose-reduced FLA-IDA (fludarabine 30 mg/m2 day 1–4, cytarabine 2000 mg/m2 day 1–4, idarubicin 10 mg/m2 day 1 + 4). From 2019 onwards, venetoclax was added (day 1 100 mg, day 2 200 mg, day 3–14 400 mg); Results: Significantly improved response rates were observed with 60.0% vs. 38.8% CR/CRi (p = 0.0297) and 74.5% vs. 47.3% (p = 0.032) CR/CRi/MLFS for FLA-VIDA vs. FLA-IDA. Further, with FLA-VIDA significantly improved event-free survival (EFS) was observed (p = 0.026). Overall survival (OS) was similar in FLA-VIDA and FLA-IDA treated patients. The most common treatment-related toxicities were hematological adverse events, but they were comparable between groups. The time to neutrophil and platelet recovery were similar in responding patients treated with FLA-VIDA vs. FLA-IDA; Conclusions: Dose-reduced FLA-VIDA significantly improved response rates without increases in toxicity, showing promise for an improved R/R AML treatment.

6 May 2025 in Research Square
Verified
Preprint
Open access
PDF file
MAMaximilian Al-Bazaz
Maximilian Al-Bazaz
SPSven Pischke
Sven Pischke
WAWinfried Alsdorf
Winfried Alsdorf
PSPiet Sonnemann
Piet Sonnemann
SCSophia Cichutek
Sophia Cichutek
RKRicardo Kosch
Ricardo Kosch
Hepatitis E virus (HEV) is an under-recognized cause of viral hepatitis, with rising incidence in high-income countries largely driven by zoonotic transmission. Patients with multiple myeloma are especially vulnerable to HEV, yet recommendations for antiviral treatment and impact on the management of myeloma treatment are missing. Here, we describe seven patients (five males, two females) with multiple myeloma who were diagnosed with HEV infection at a tertiary care center in Western Europe within less than one year. All cases were confirmed by positive HEV-RNA PCR in the peripheral blood. Although no instances of fulminant hepatitis were observed, HEV infection led to substantial treatment delays. Ribavirin was initiated in four cases. The three patients undergoing T-cell redirecting therapies, including one with prior ciltacabtagen autoleucel and two on bispecific antibodies, progressed to chronic HEV infection despite ribavirin treatment. One patient, despite clearing HEV from peripheral blood, developed persistent vertigo and tested positive for HEV-RNA in the cerebrospinal fluid, indicating neuroinvasion. As the largest reported cohort of myeloma patients with HEV infections, this study emphasizes the urgent need to increase awareness of HEV as an emerging threat, refine screening protocols, and establish standardized therapeutic strategies in the era of novel immunotherapeutic approaches.